The Global TAVR (Transcatheter Aortic Valve Replacement) Market was valued at USD 6.6 billion in 2025 and is estimated to grow at a CAGR of 9.8% to reach USD 16.5 billion by 2035.
The TAVR (Transcatheter Aortic Valve Replacement) market continues to experience strong growth as transcatheter valve procedures become an increasingly preferred treatment option for patients with aortic stenosis across a broader range of clinical risk categories. Expanding clinical evidence demonstrating favorable patient outcomes compared with conventional treatment approaches continues to support wider physician acceptance and procedural adoption. Long-term market expansion is further driven by the rapid growth of the aging population, increasing prevalence of cardiovascular disorders, and ongoing improvements in healthcare reimbursement across developed economies. Advances in valve technology, enhanced procedural planning, and continuous innovation in imaging capabilities are improving treatment precision while supporting broader clinical application. As life expectancy rises worldwide, the number of patients eligible for transcatheter valve replacement continues to increase, creating sustained demand for minimally invasive cardiac interventions. Healthcare systems across North America, Europe, and Asia-Pacific are also expanding access to advanced cardiovascular care, encouraging higher procedural volumes and reinforcing favorable long-term growth prospects for the global TAVR (Transcatheter Aortic Valve Replacement) market.
The balloon-expandable valves segment accounted for 55% share in 2025 and is projected to grow at a CAGR of 9.6% through 2035, making them the leading deployment type. The segment maintains its dominant position because balloon-expandable systems provide highly accurate valve placement, reliable deployment performance, and consistent hemodynamic outcomes. Their established clinical performance, long-term durability, and predictable procedural characteristics continue to support widespread adoption among healthcare providers, contributing significantly to procedural growth across the global market.
The hospitals segment held 82% share in 2025 and is expected to grow at a CAGR of 9.6% during 2026-2035. Hospital settings remain the primary end users because transcatheter valve replacement procedures require advanced cardiac catheterization facilities, multidisciplinary clinical teams, specialized patient monitoring capabilities, and comprehensive emergency care infrastructure. High-volume cardiovascular treatment centers continue to perform the majority of procedures, supported by experienced clinical teams and well-established structural heart programs that ensure safe and effective patient care.
North America TAVR (Transcatheter Aortic Valve Replacement) Market accounted for 46% share in 2025 and is projected to grow at a CAGR of 9.6% through 2035. The United States remains the largest contributor to regional demand, while Canada also represents an important market supported by its established healthcare system. Market growth across the region continues to benefit from favorable reimbursement policies, expanding patient eligibility, growing physician adoption, and increasing availability of specialized treatment centers, all of which continue to support higher procedural volumes and sustained market expansion.
Major companies operating in the Global TAVR (Transcatheter Aortic Valve Replacement) market include Medtronic, Edwards Lifesciences, Abbott Laboratories, Boston Scientific Corporation, LEPU Medical, MicroPort, Venus Medtech, Meril Life Sciences, Peijia Medical, JenaValve Technology, Foldax, Bracco, and Anteris Technologies. Companies operating in the TAVR (Transcatheter Aortic Valve Replacement) market are strengthening their competitive position by investing heavily in research and development to improve valve performance, procedural safety, and long-term clinical outcomes. Manufacturers continue to expand product portfolios through technological innovation while focusing on minimally invasive treatment solutions that improve physician confidence and patient recovery. Strategic collaborations with healthcare providers, clinical research organizations, and academic institutions are supporting product development and expanding clinical adoption.
This product will be delivered within 2-4 business days.
The TAVR (Transcatheter Aortic Valve Replacement) market continues to experience strong growth as transcatheter valve procedures become an increasingly preferred treatment option for patients with aortic stenosis across a broader range of clinical risk categories. Expanding clinical evidence demonstrating favorable patient outcomes compared with conventional treatment approaches continues to support wider physician acceptance and procedural adoption. Long-term market expansion is further driven by the rapid growth of the aging population, increasing prevalence of cardiovascular disorders, and ongoing improvements in healthcare reimbursement across developed economies. Advances in valve technology, enhanced procedural planning, and continuous innovation in imaging capabilities are improving treatment precision while supporting broader clinical application. As life expectancy rises worldwide, the number of patients eligible for transcatheter valve replacement continues to increase, creating sustained demand for minimally invasive cardiac interventions. Healthcare systems across North America, Europe, and Asia-Pacific are also expanding access to advanced cardiovascular care, encouraging higher procedural volumes and reinforcing favorable long-term growth prospects for the global TAVR (Transcatheter Aortic Valve Replacement) market.
The balloon-expandable valves segment accounted for 55% share in 2025 and is projected to grow at a CAGR of 9.6% through 2035, making them the leading deployment type. The segment maintains its dominant position because balloon-expandable systems provide highly accurate valve placement, reliable deployment performance, and consistent hemodynamic outcomes. Their established clinical performance, long-term durability, and predictable procedural characteristics continue to support widespread adoption among healthcare providers, contributing significantly to procedural growth across the global market.
The hospitals segment held 82% share in 2025 and is expected to grow at a CAGR of 9.6% during 2026-2035. Hospital settings remain the primary end users because transcatheter valve replacement procedures require advanced cardiac catheterization facilities, multidisciplinary clinical teams, specialized patient monitoring capabilities, and comprehensive emergency care infrastructure. High-volume cardiovascular treatment centers continue to perform the majority of procedures, supported by experienced clinical teams and well-established structural heart programs that ensure safe and effective patient care.
North America TAVR (Transcatheter Aortic Valve Replacement) Market accounted for 46% share in 2025 and is projected to grow at a CAGR of 9.6% through 2035. The United States remains the largest contributor to regional demand, while Canada also represents an important market supported by its established healthcare system. Market growth across the region continues to benefit from favorable reimbursement policies, expanding patient eligibility, growing physician adoption, and increasing availability of specialized treatment centers, all of which continue to support higher procedural volumes and sustained market expansion.
Major companies operating in the Global TAVR (Transcatheter Aortic Valve Replacement) market include Medtronic, Edwards Lifesciences, Abbott Laboratories, Boston Scientific Corporation, LEPU Medical, MicroPort, Venus Medtech, Meril Life Sciences, Peijia Medical, JenaValve Technology, Foldax, Bracco, and Anteris Technologies. Companies operating in the TAVR (Transcatheter Aortic Valve Replacement) market are strengthening their competitive position by investing heavily in research and development to improve valve performance, procedural safety, and long-term clinical outcomes. Manufacturers continue to expand product portfolios through technological innovation while focusing on minimally invasive treatment solutions that improve physician confidence and patient recovery. Strategic collaborations with healthcare providers, clinical research organizations, and academic institutions are supporting product development and expanding clinical adoption.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Deployment Type, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Implantation Procedures, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Material, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 10 Company Profiles
Companies Mentioned
- Abbott Laboratories
- Anteris Technologies
- Boston Scientific Corporation
- Bracco
- Edwards Lifesciences
- Foldax
- JenaValve Technology
- LEPU Medical
- Medtronic
- Meril Life Sciences
- MicroPort
- Peijia Medical
- Venus Medtech
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | July 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 6.6 Billion |
| Forecasted Market Value ( USD | $ 16.5 Billion |
| Compound Annual Growth Rate | 9.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
